The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mr. Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, along with Persons Acting in Concert (PACs), bought 4,800 equity shares (2,400 each on March 19 and March 20, 2026) through open market purchases. This represents 0.21% of the company's total equity share capital. The promoter group's combined holding rose from 14,55,800 shares (63.78%) to 14,60,600 shares (63.99%). The company's total equity share capital remains 22,82,400 shares. The disclosure is filed under Regulation 29(2) of SEBI Takeover Regulations.
This is a minor accumulation by an already-dominant promoter group, reinforcing their majority control (~64%). The purchase size is too small to materially affect stock price, but signals continued promoter confidence in the company.